Insulet Corporation $PODD Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 2.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 773,361 shares of the medical instruments supplier’s stock after selling 21,986 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Insulet were worth $117,744,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Larson Financial Group LLC boosted its position in shares of Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 47 shares during the period. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Insulet during the fourth quarter worth about $26,000. DV Equities LLC acquired a new position in Insulet during the 4th quarter worth approximately $28,000. Elyxium Wealth LLC acquired a new position in shares of Insulet during the fourth quarter worth $28,000. Finally, Mcguire Capital Advisors Inc. acquired a new position in shares of Insulet during the 4th quarter worth about $29,000.

Insulet Stock Down 0.2%

PODD opened at $148.38 on Wednesday. The business has a 50 day moving average price of $154.74 and a two-hundred day moving average price of $179.24. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. The company has a market cap of $10.29 billion, a PE ratio of 27.73, a P/E/G ratio of 1.17 and a beta of 1.08. Insulet Corporation has a 52 week low of $126.40 and a 52 week high of $354.88.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.19. The company had revenue of $801.70 million for the quarter, compared to the consensus estimate of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The company’s revenue was up 23.5% on a year-over-year basis. During the same period last year, the business posted $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, research analysts anticipate that Insulet Corporation will post 6.51 EPS for the current year.

Analyst Ratings Changes

PODD has been the subject of several recent analyst reports. JPMorgan Chase & Co. restated a “neutral” rating and set a $152.00 price objective (down from $275.00) on shares of Insulet in a research report on Thursday, August 6th. Royal Bank Of Canada cut their price target on shares of Insulet from $245.00 to $160.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Jefferies Financial Group reduced their price target on shares of Insulet from $400.00 to $360.00 in a research report on Thursday, May 7th. Stifel Nicolaus decreased their price objective on shares of Insulet from $225.00 to $180.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Finally, Evercore set a $180.00 price objective on Insulet in a report on Monday, July 6th. Fourteen equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $195.40.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.